ASPIC

send to a friend share this

New study increases the precision of the detection of circulating tumor cells

Circulating tumour cells, commonly known as CTCs, are live tumour cells released by the active tumour into blood circulation, which allows them to travel through the body and potentially form new tumour in other organs, or metastases. The enumeration of CTCs holds prognostic information but, most importantly, CTCs can serve to evaluate the presence of druggable targets, enabling the oncologist to continuously monitor the patients non-invasively and adjust their treatment in a personalised manner. The study of CTCs is also crucial to better understand their role in the metastatic cascade.

Novo estudo aumenta a precisão da deteção de células tumorais circulantes

As células tumorais circulantes, frequentemente conhecidas como CTCs, são células viáveis libertadas pelo tumor primário para a corrente sanguínea, o que lhes permite deslocarem-se para qualquer parte do organismo e potencialmente formar metástases, levando ao desenvolvimento de tumores secundários. Para compreender melhor o papel das CTCs na cascata metastática, é crucial capturar, identificar e caracterizar estas células. No entanto, esta população heterogénea de células é também rara, o que dificulta o seu isolamento e identificação.

5th International Conference on Lymphocyte Engineering (ICLE 2025)

Munich, Germany

 

20-22 February, 2025

 

See more informations here: https://lymphocyte.kenes.com/

5th International Conference on Lymphocyte Engineering (ICLE 2025)

Munich, Germany

 

20-22 February, 2025

 

See more informations here: https://lymphocyte.kenes.com/

Dissecting the genetic drivers of thyroid cancer metastization

Valdemar Máximo, Arnaud Da Cruz Paula and Paula Soares from the Cancer Signaling & Metabolism group at i3S have always wanted to know more about the genomic profiling of primary and metastatic thyroid cancers. Hence, they decided to meticulously characterize the genomic features of these neoplasms.

 

Dissecando o perfil genético da metastização do cancro da tiróide

O Valdemar Máximo, Arnaud Da Cruz Paula e a Paula Soares do grupo Cancer Signalling & Metabolism do i3S sempre quiseram saber mais sobre o perfil genómico dos tumores primários e metastáticos da tiróide. Deste modo, decidiram caracterizar meticulosamente as particularidades genómicas destas neoplasias.

 

EACR 2025 Congress: Innovative Cancer Science

Lisbon Congress Centre, Praça das Indústrias 1, Lisboa, Portugal

 

16-19 June, 2024

 

See more informations here: https://2025.eacr.org/venue

 

Don't miss the “ASPIC - EACR Joint Symposium” at 10:20 AM on June 16, the first day of the EACR Congress 2025.
Brought to you with the support of our dedicated sponsors: Lilly, ThermoFisher, Amgen and Merck.

EACR 2025 Congress: Innovative Cancer Science

Lisbon Congress Centre, Praça das Indústrias 1, Lisboa, Portugal

 

16-19 June, 2024

 

See more informations here: https://2025.eacr.org/venue

 

Don't miss the “ASPIC - EACR Joint Symposium” at 10:20 AM on June 16, the first day of the EACR Congress 2025.
Brought to you with the support of our dedicated sponsors: Lilly, ThermoFisher, Amgen and Merck.

EACR-Boehringer Ingelheim Conference: Drugging and Regulating the MAP Kinase Pathway

Extracellular vesicles in tumor-adipose tissue crosstalk: key drivers and therapeutic targets in cancer cachexia

More than half of all advanced cancer patients will experience cachexia at any point in their disease. Patients with cancer cachexia often experience unintentional weight loss mainly due to the progressive loss of body fat and skeletal muscle. This metabolic disorder severely impacts patients’ quality of life, treatments, and survival. Although nutritional supplementation is recommended in cancer cachexia patients, this solution is not capable of reversing cachexia symptoms.